Theraclion SA (FRA:941)

Germany · Delayed Price · Currency is EUR

0.6120

-0.0340 (-5.26%)

At close: Sep 11, 2026

Market Cap	47.67M +41.3%
Revenue (ttm)	652.00K -21.4%
Net Income	-5.69M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.6460
Previous Close	0.6460
Day's Range	0.6120 - 0.6460
52-Week Range	0.4360 - 0.9300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 14, 2026

About Theraclion

Theraclion SA provides therapeutic ultrasound technology for seamless vein care. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient’s skin and optimize image quality. The company was incorporated in 2004 and is headquartered in Malakoff, France. [Read more]

Industry Electromedical and Electrotherapeutic Apparatus

Founded 2004

Employees 36

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 941

Financial Performance

In 2025, Theraclion's revenue was 652,000, a decrease of -21.35% compared to the previous year's 829,000. Losses were -5.69 million, -1.16% less than in 2024.

Financial Statements